Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABBVIE INC.

(ABBV)
  Rapport
Vertraagde tijd Nyse  -  22:03 03-10-2022
138.32 USD   +3.06%
27/09AbbVie Inc. Kondigt XEN® 63 Gel Implantaat aan, nu beschikbaar voor patiënten met Primair Open Hoek Glaucoom waar eerdere medische behandelingen hebben gefaald.
CI
22/09Amerikaanse aandelen eindigen donderdag lager ondanks stijgingen in de gezondheidszorg
MT
22/09Amerikaanse aandelen eindigen donderdag lager ondanks stijging aandelen gezondheidszorg
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société ABBVIE INC.
14:01AbbVie to Host Third-Quarter 2022 Earnings Conference Call
PR
29/09AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease an..
PR
27/09XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where p..
AQ
23/09AbbVie - The Forces of Beauty Report from the DREAM Initiative Reveals Demand for New S..
AQ
20/09AbbVie Secures Positive CHMP Opinion for Risankizumab for the Treatment of Adults with ..
AQ
19/09AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of A..
PR
15/09AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 20..
PR
14/09Allergan Aesthetics and BOTOX Cosmetic Reveal New 'See Yourself' Campaign Cast, Spotlig..
AQ
13/09Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' ..
PR
12/09Abbvie - New Late-Breaking Results from Phase 3 Trials of SKYRIZI Evaluating Long-term ..
AQ
12/09AbbVie Declares Quarterly Dividend
AQ
09/09AbbVie Declares Quarterly Dividend
PR
09/09AbbVie - New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens i..
AQ
08/09Allergan Aesthetics Celebrates 100 Million Syringes of JUVEDERM
AQ
08/09New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic ..
PR
08/09AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust Interna..
PR
07/09Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®
PR
07/09AbbVie to Present at the Morgan Stanley Healthcare Conference
PR
01/09AbbVie - SkinMedica Launches Firm and Tone Lotion for Body
AQ
31/08SkinMedica® Launches Firm & Tone Lotion for Body
PR
30/08AbbVie Showcases New Analyses and Real-World Data across Multiple Immune-Mediated Skin ..
AQ
29/08AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin ..
PR
25/08Abbvie - Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed ..
AQ
25/08Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA..
PR
18/08Allergan Aesthetics - Experience the JUVEDERM Difference with Allergan Aesthetics
AQ
17/08Experience the JUVÉDERM® Difference with Allergan Aesthetics
PR
11/08The Seventh Circuit Asks, "What's Wrong With Having Lots Of Patents?"
AQ
04/08ABBVIE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
04/08AbbVie's Humira Patent Settlement Not A Violation Of Sherman Antitrust Act, Seventh Cir..
AQ
04/08FDA Approves JUVEDERM VOLUX XC for Improvement of Jawline Definition
AQ
03/08FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
PR
01/08AbbVie - RINVOQ (upadacitinib) Approved by European Commission as an Oral Treatment for..
AQ
01/08AbbVie Reports Second-Quarter 2022 Financial Results
AQ
29/07Abbvie : Reports Second-Quarter 2022 Financial Results - Form 8-K
PU
29/07Abbvie : Q2 Earnings Snapshot
AQ
29/07RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults ..
PR
28/07AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Croh..
AQ
27/07AbbVie - European Commission Approves RINVOQ (upadacitinib) for the Treatment of Adults..
AQ
27/07AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Cro..
PR
26/07European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Mo..
PR
25/07AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at..
PR
20/07Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with..
AQ
20/07AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
PR
19/07Genmab Announces That AbbVie Will Submit Marketing Authorization Application to Europea..
AQ
18/07Genmab Announces That AbbVie Will Submit Marketing Authorization Application to Europea..
BU
11/07AbbVie to Host Second-Quarter 2022 Earnings Conference Call
AQ
08/07AbbVie to Host Second-Quarter 2022 Earnings Conference Call
PR
06/07Abbvie : Results of Operations and Financial Condition - Form 8-K
PU
29/06Abbvie Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S..
AQ
28/06AbbVie - CHMP Recommends Approval of Upadacitinib (RINVOQ) for the Treatment of Adults ..
AQ
28/06Abbvie Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
27/06CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Act..
PR
23/06AbbVie Declares Quarterly Dividend
PR
22/06MAVIRET® (glecaprevir/pibrentasvir) Approved by Health Canada for Paediatric Patients w..
AQ
20/06SKYRIZI (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interl..
AQ
17/06SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Inter..
PR
13/0624/7 Market News : 5 Pharma Company Analyst Targets and most Bullish Argument for each
AQ
13/065 Pharma Company Analyst Targets and most Bullish Case for each
AQ
13/06AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritama..
AQ
11/06AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritama..
PR
10/06AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myel..
PR
10/06New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-..
PR
08/06AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Heada..
AQ
02/06AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RIN..
AQ
01/06AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RIN..
PR
01/06Abbvie : Launches New Data Sharing Platform to Connect Real-World Health Data to Clinical ..
PU
27/05The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating..
PR
27/05The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating..
PR
25/05AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
PR
24/05AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR) for the Adjun..
AQ
24/05CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ) for the Treatment..
AQ
24/05AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple ..
PR
23/05AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbid..
AQ
23/05CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatmen..
PR
20/05AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbid..
PR
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op ABBVIE INC.